Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Fractal Gaming Group Interim Report January-September 2023

Third quarter 2023 · Net sales amounted to SEK 189.9 million (131.0). · Product profit amounted to SEK 79.3 million (50.2), with a product margin of 41.8% (38.3). · EBITDA amounted to SEK 35.1 million (12.5), corresponding to an EBITDA margin of 18.5% (9.5). · EBIT amounted to SEK 29.8 million (7.5), corresponding to an EBIT margin of 15.7% (5.7). · Operating cash flow amounted to SEK 65.0 million (12.2). · Interest-bearing net debt was SEK -75.5 million (126.0). · Earnings per share amounted to SEK 0.8 (0.2). · No items affecting comparability for the quarter.

ZINZINO AB (PUBL): INTERIM REPORT THIRD QUARTER 2023

GOING TOWARDS RECORD RESULTS IN 2023 AFTER ANOTHER VERY STRONG QUARTER The total revenues during the third quarter of 2023 amounted to SEK 436.9 (349.9) million, which corresponded to 25% (12%) growth compared to the corresponding quarter of the previous year. The EBITDA result increased to SEK 71.2 (25.4) million for the quarter and the EBITDA margin increased to 16.3% (7.3%). As before, behind the margin improvement are primarily changes in the sales mix, efficiencies and economies of scale. During the quarter, a very successful sales launch was carried out in Mexico and BalanceTest no.

Millions to lose sight of spending as monthly subscriptions and payment deferrals pile pressure on household finances

· Almost half (45%) of European consumers are caught out by the build-up of monthly subscription costs · Generation gap means over half (52%) of millennials and 53% of Gen Z struggle to keep track of subscription spending, compared with 34% of Baby boomers · 30% of consumers are planning to increase their use of buy-now-pay-later products · Three in four (76%) are just breaking even or are over-spending each month, with the average over-spender exceeding their budget by EUR 232 · One in five consumers have no ‘cash buffer’ to fall back on in the event of difficultiesMillions of

Genetic Analysis – Capital raise give boost – Mangold Insight Analysis

Genetic Analysis, a diagnostic company within Life Science, is growing rapidly. To continue its expansion, the company needs to raise capital, expected to be done in several steps. First, in a direct issue to a group of existing shareholders, followed by a repair rights issue directed to existing shareholders. Its partner in China, is also expected to invest in the company early next year. In total, the company is expected to be able to raise up to NOK 25 million. This enables continued growth that will take the company to profitability.The third quarter was soft due to earlier stock-

SciBase and Skin and Cancer Institute partner to advance AI-driven skin cancer detection in California

STOCKHOLM, SWEDEN, - November 16, 2023 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced today that they have entered into a collaboration agreement with the Skin and Cancer Institute to pilot Nevisense in several of their California locations. The Skin and Cancer Institute is a world-renowned dermatology practice group of dermatologists and skin cancer surgeons, and will be the first dermatology practice group in California to bring AI-driven technology to their patients for skin cancer detection. With more

Metsä Group’s insect damage application awarded as the best innovation in Finland

An artificial intelligence application developed by Metsä Group and CollectiveCrunch for detecting insect damage in forests has won the Quality Innovation Award in a competition organised by the Finnish Quality Association, Excellence Finland. Metsä Group’s Future Sawmill concept won the Business Innovation category of the competition. The Finnish Quality Association presented the awards on Wednesday 15 November. The award-winning application from Metsä Group and CollectiveCrunch detects insect damage in forests such as damage caused by spruce bark beetles before it is visible to the

Höegh LNG: Interim results for the quarter ended 30 September 2023

Hamilton, Bermuda, 16 November 2023 - Höegh LNG Holdings Ltd. ("Höegh LNG") today reports its interim financial results for the quarter ended 30 September 2023. The group reported a total income of USD 140 million and an EBITDA of USD 89 million for the third quarter of 2023, compared to USD 127 million and USD 79 million for the preceding quarter.Furthermore, in the third quarter Höegh LNG entered into a strategic partnership with Aker BP to develop a fully comprehensive carbon transport and storage (CCS) offering for industrial CO2 emitters in Northern Europe.  Subsequent to the

Half-year Report

16 November 2023   PHSC PLC (“PHSC”, the “Company” or the “Group”)   Unaudited Interim Results for the six months ended 30 September 2023   PHSC (AIM: PHSC), a leading provider of health, safety, hygiene and environmental consultancy services and security solutions to the public and private sectors, is pleased to announce its unaudited interim results for the six-month period ended 30 September 2023.   GROUP CHIEF EXECUTIVE OFFICER’S STATEMENT   Financial Highlights · Group revenue of £1.651m (H1 FY23: £1.679m). · EBITDA of £174k (H1 FY23: £162k).

Key results of Sedana Medical’s paediatric study IsoCOMFORT published

Sedana Medical AB (publ) today announces that the main results from the paediatric IsoCOMFORT study have been published in the Clinical Trials Registry EudraCT.IsoCOMFORT was a randomised active-controlled assessor-blinded study comparing the efficacy and safety of sedation with inhaled isoflurane, administered via the company’s medical device Sedaconda ACD-S, with intravenous midazolam in mechanically ventilated paediatric patients 3 to 17 years old. The primary endpoint was to compare the time that the targeted sedation depth was maintained. Key secondary endpoints included opioid

Implantica’s RefluxStop[TM] health economic research, showing superior cost-effectiveness, has received top-recognition at ISPOR, the world’s leading European Health-Economics Conference

Implantica AG (publ.), a medtech company at the forefront of bringing advanced technology into the body, presented an abstract on cost-effectiveness analysis in Sweden, which was recognized among the Top 5% Posters category for its high scientific quality at the ISPOR Europe conference 2023 (International Society for Pharmacoeconomics and Outcomes Research) in Copenhagen, Denmark.The in-depth and comprehensive health economic analyses in Sweden and Switzerland including four successful abstracts demonstrates that RefluxStop™ is more cost-effective against existing treatment options. The

Transcom Holding AB (publ): Third quarter report 2023

Third quarter 2023 highlights · Revenue increased to 180.6M€ (177.5) · EBITDA excluding non-recurring items increased to 25.1M€ (23.0) · EBITDA margin excluding non-recurring items increased to 13.9% (13.0%) · Operating cash flow decreased to 9.4M€ (12.2) · Net debt/EBITDA decreased to 3.5 (3.7) January – September 2023 · Revenue increased to 548.2M€ (525.9) · EBITDA excluding non-recurring items increased to 70.6M€ (62.9) · EBITDA margin excluding non-recurring items increased to 12.9% (12.0%) · Operating cash flow increased to 33.1M€ (27.5) · Net debt/

GomSpace reports a strong improvement in the free cash flow for the third quarter of 2023

In the Q3 2023 interim report, GomSpace reports a strong progress of the financial turnaround as free cash flow is improved with T.SEK 36.095 compared to the first quarter this year. In addition, the company projects full year revenue to reach highest level since the company was founded.GomSpace Group AB (the “Company”) announces its interim report for the third quarter of 2023. HighlightsThird quarter 2023 (2022) · Order intake was T.SEK 39,011 (52,639) · Net revenues increased significantly by 274% to T.SEK 67,706 (18,102) · Gross margin increased to 15% (negative 298%)

UNION therapeutics A/S completes patient enrollment for ADESOS Phase 2b study of orismilast in patients with atopic dermatitis

· Topline results are expected in the first half of 2024 · Atopic dermatitis (AD) is the most common chronic inflammatory skin disease in the developed world and a significant unmet medical need exists for safe oral treatments · Orismilast is a next-generation, high potency PDE4 B/D selective inhibitor with recently reported positive Phase 2 results in psoriasis and hidradenitis suppurativa (HS)   Hellerup, Denmark, November 16, 2023 – UNION therapeutics A/S (UNION), a privately-held, clinical stage, pharmaceutical development company focused on immunology and infectious

Interim report 1 January – 30 September 2023

Q3 2023: Weak operationally. Key strategically.THIRD QUARTER 2023 · Revenue increased by 56% to SEK 643m (412) · Operating profit adjusted[1] decreased by 37% to SEK -28m (-21) · Operating profit decreased by 109% to SEK -28m (300) · Operating margin adjusted[1] increased to -4.4% (5.0) · The result for the period decreased by 124% to SEK -89m (366) · Basic earnings per share[2] amounted to SEK -6.16 (25.20) · Cash flows from operating activities amounted to SEK -88m (240) JANUARY - SEPTEMBER 2023 · Revenue increased by 54% to SEK 1,948m (1,268) · Operating

Borr Drilling Limited Announces Third Quarter and Nine Months 2023 Results

Hamilton, Bermuda, November 16, 2023: Borr Drilling Limited (“Borr”, “Borr Drilling” or the “Company”) announces unaudited results for the three and nine months ended September 30, 2023. Highlights Third Quarter of 2023 · Total operating revenues of $191.5 million, an increase of $4.0 million or 2% compared to the second quarter of 2023. · Net income of $0.3 million, a decrease of $0.5 million compared to the second quarter of 2023. · Adjusted EBITDA of $88.2 million, an increase of $4.2 million or 5% compared to the second quarter of 2023. · Total contract revenue

Skanska at COP28 global climate summit: scaling up solutions

Skanska, a recognized climate leader in the development and construction industry, will be at COP28 to join with customers, partners and policymakers to scale up global solutions for a more sustainable built environment.  COP28, the 28th United Nations Climate Change Conference of the Parties, is a global climate summit being held in Dubai, the United Arab Emirates, from 30 November, where countries are coming together to negotiate actions to address climate change.At COP28, our leaders will highlight Skanska’s and the industry’s crucial role in the energy transition, including how we can

Greater Than’s data analytics enables ABAX to launch connected fleet insurance brand, Fair

·Fair is a new, independent car insurance broker brand developed to deliver data-driven value to connected fleet insurance customers.  ·As a spinoff of ABAX, one of Europe’s largest telematics companies, Fair will initially offer the insurance to ABAX’s current customers in Sweden, a volume of 200,000+ connected vehicles.   ·Greater Than’s AI is used to segmentize and price risk, enabling transparent pricing and concrete support to customers to help avoid crashes.  Greater Than (GREAT.ST), the global provider of driver crash probability and climate impact intelligence,

Interim Report for January 1, 2023 to September 30, 2023

· Net turnover in the period amounted to 57 102 TSEK (20 246 TSEK). Net turnover in the third quarter amounted to 17 968 TSEK (7 103 TSEK). · Earnings before interest and taxes (EBIT) amounted to -6 660 TSEK (-13 805 TSEK). Earnings before interest and taxes (EBIT) in the third quarter amounted to -2 439 TSEK (-3 641 TSEK) · The result after financial items amounted to -12 285 TSEK (-17 453 TSEK). The result after financial items in the third quarter amounted to -4 008 TSEK (-4 877 TSEK). · The result per share amounted to -0,027 SEK (- 0,12 SEK) in the period. The result per

Aquaporin Q3 2023 Trading Statement – continued strong momentum with quarterly revenue growth of 164 %

Aquaporin A/S, Nymøllevej 78, DK-2800 Kongens Lyngby, aquaporin.com, Company registration no.: DK28315694Company announcementNo. 30/2023 Copenhagen, Denmark, November 16, 2023– Aquaporin A/S (ticker: AQP) (“Aquaporin” or the “Company”), an innovative water technology company dedicated to rethinking water filtration with biotechnology, today announces the Company's Q3 2023 Trading Statement for the period January 1-September 30, 2023. “We maintained strong momentum in the third quarter of 2023 with a 164% revenue growth compared to the same period last year. We are seeing significant

Aquaporin introduces preliminary guidance for 2024 and maintains guidance for 2023

Aquaporin A/S, Nymøllevej 78, DK-2800 Kongens Lyngby, aquaporin.com, Company registration no.: DK28315694Company announcementNo. 29/2023 Copenhagen, Denmark, November 16, 2023 – Aquaporin A/S (ticker: AQP) (“Aquaporin” or the “Company”), an innovative water technology company dedicated to rethinking water filtration with biotechnology, today introduces preliminary guidance for the fiscal year 2024: · In 2024, the Company expects further strong growth in revenue to approximately DKK 100 million. · At this point, the Company has visibility on more than DKK 50 million of the

High concentration of glycoalkaloids in foreign potato flakes confirmed as the cause of pets falling ill

Musti Group plc                                                                Press release 16 November 2023 8:00 For the past two weeks, we have worked in close cooperation with the Finnish Food Authority, veterinarians, and suppliers to determine the cause of adverse reactions in pets.   The recent externally conducted laboratory analysis has now verified that the reason for pets falling ill is the high concentration of glycoalkaloids found in the foreign potato flakes. Testing was performed on both the raw material and the food product, revealing elevated levels of glycoalkaloids

Green Landscaping Group (publ) Interim report January-September 2023

16 November 2023, 07:00 CET July-September 2023   · Net sales amounted to SEK 1,430 (1,176) million. · Growth was 22 percent, of which organic growth amounted to 0 percent. · EBITA increased by 45 percent to SEK 128 (89) million. · EBITA margin amounted to SEK 9.0 (7.6) percent. · Cash flow from operating activities amounted to SEK –2 (53) million. · Basic earnings per share were SEK 0.84 (0.89). · Diluted earnings per share were SEK 0.84 (0.88).   CEO comments   The third quarter was yet another success for Green Landscaping Group. Net sales

Circio joins collaboration to test the combination of TG01 vaccination with daratumumab and nivolumab in immunotherapy resistant patients with mutant RAS cancers

· Circio joins Georgetown University-sponsored phase 2 clinical trial to test TG01 mutant RAS cancer vaccine in combination with daratumumab from Janssen and nivolumab from BMS · The innovative combination will be tested in immunotherapy-resistant pancreatic and lung cancer and led by world-renowned immunotherapy expert Prof. Samir N. Khleif · The trial has been given approval to proceed by the US Food and Drug Administration (FDA), and will start enrolling patients by the end of 2023Oslo, Norway, 16 November 2023 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing

There are no items matching the current filter
There are no more items matching the current filter
Back to top